Geode Capital Management LLC Has $1.86 Million Position in INmune Bio, Inc. (NASDAQ:INMB)

Geode Capital Management LLC raised its stake in INmune Bio, Inc. (NASDAQ:INMB) by 6.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 344,466 shares of the company’s stock after acquiring an additional 21,262 shares during the quarter. Geode Capital Management LLC’s holdings in INmune Bio were worth $1,857,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. State Street Corp increased its position in INmune Bio by 35.1% in the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after buying an additional 58,838 shares in the last quarter. CVI Holdings LLC bought a new position in shares of INmune Bio in the 2nd quarter worth $5,260,000. Rhumbline Advisers acquired a new stake in INmune Bio in the 2nd quarter valued at $121,000. Barclays PLC raised its holdings in INmune Bio by 601.9% during the third quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after buying an additional 24,906 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of INmune Bio in the third quarter valued at $249,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Stock Down 4.8 %

INMB stock opened at $5.30 on Thursday. The firm has a market cap of $117.51 million, a PE ratio of -2.43 and a beta of 1.78. The business has a 50 day moving average of $5.16 and a 200-day moving average of $6.18. INmune Bio, Inc. has a 12-month low of $4.32 and a 12-month high of $14.74.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 117.48%. During the same period in the prior year, the company posted ($0.48) earnings per share. On average, research analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

INMB has been the topic of a number of analyst reports. Alliance Global Partners started coverage on shares of INmune Bio in a report on Monday, October 21st. They issued a “buy” rating and a $20.00 target price on the stock. Raymond James initiated coverage on INmune Bio in a report on Friday, September 27th. They set an “outperform” rating and a $18.00 price target for the company.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.